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The objective is to compare robotic sacral colpopexy (RSC) utilizing autologous fascia lata 
to RSC with synthetic mesh in the treatment of pelvic organ prolapse. 
Methods 
We performed a prospective non-randomized case comparison trial at a single institution. 
We compared RSC utilizing either synthetic mesh or autologous fascia lata in women with 
symptomatic pelvic organ prolapse, stages II through IV. The primary outcome was 
anatomic prolapse recurrence determined by the Pelvic Organ Prolapse Quantification 
(POP-Q) exam. Secondary outcomes included patient reported outcomes such as the 
Urogenital Distress Inventory-6 (UDI-6) and Incontinence Impact Questionnaire-7 (IIQ-7). 
Complications were also recorded and categorized using the Clavien-Dindo system (CD). 
The hypothesis is that autologous fascia lata would provide equivalent anatomic and 
patient reported outcomes compared to mesh while eliminating mesh related 
complications.  
Results 
Sixty-four women underwent RSC with 19 (29.7%) receiving fascia lata graft. The overall 
operative time was greater in the fascia lata group with mean fascia lata harvest time of 
24.8±7.4 minutes. Intragroup comparisons of the fascia and mesh groups demonstrated 
significant improvement in pelvic measurements as well as patient reported outcomes. 
Intergroup comparison demonstrated equivalent success rates at 12.1±8.7 months follow 
up. There was one apical failure in the fascia lata RSC group, however the difference was 
not statistically significant (p=0.30). Significant complications in the fascia lata harvest 
group included two CD-II and one CD-IIIb. In the mesh group there was one mesh erosion 
requiring surgical excision (CD-IIIb).   
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Conclusion 
This is the first comparison between RSC with autologous fascia lata vs. mesh. Short-term 
anatomic outcomes were similar with autologous fascia lata use without the risk of mesh 
erosion. Morbidity from graft harvest site was not trivial. These results emphasize the 
need for a randomized controlled trial.  
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Introduction 
Pelvic floor disorders include a variety of clinical conditions including pelvic organ prolapse 
(POP), urinary incontinence, and fecal incontinence.1 POP includes anterior vaginal 
prolapse, apical or uterine descent, and posterior vaginal prolapse.1 POP is a common 
problem amongst the aging female population and its prevalence is steadily increasing. 
POP, when defined by symptoms, has a prevalence of 3-6%, but when based upon vaginal 
examination can be as prevalent as 50% in the female population.2 It is predicted that the 
number of women with at least one pelvic floor disorder will increase from 28.1 million in 
2010 to 43.8 million by 2050.3 
Sacral colpopexy is considered the most effective and durable treatment for advanced 
apical prolapse.4 The goal is to resuspend the vagina to its anatomically correct position by 
securing the vaginal apex to the sacrum. This can be approached using a variety of 
techniques, including the use of either autologous tissue or mesh. Latini and Kreder were 
the first to report on autologous fascia lata.5 Years later, robotic sacral colpopexy (RSC) has 
been established as a safe and effective approach. RSC has been shown to have similar 
long term outcomes when compared to the open abdominal approach, with failure rates 
of 4.2-12% depending on how failure is defined.6, 7 Previous studies have demonstrated a 
longer operative time for RSC, but decreased length of stay and blood loss.8 The number of 
RSC procedures has increased considerably in North America in recent years, making it the 
fastest growing approach for sacral colpopexy.9  
Mesh is considered the gold standard option for apical prolapse, with fewer reported 
failures than tissue based repairs.10 The main complications associated with mesh use 
include suture and mesh erosion.11 With current Food and Drug Administration (FDA) 
warnings and patient safety concerns regarding vaginal mesh, patients and surgeons have 
a renewed interest in developing alternative mesh-free solutions. Autologous fascia RSC 
has been successful with minimal apical prolapse recurrences in the short term, within a 
small series.12 To date, no comparison study has been published regarding the 
comparative efficacy and safety of mesh versus autologous fascia during RSC. We hope to 
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fill a critical need in the literature, given the prevalence of POP and the rising popularity of 
RSC.9 
We present our recent experience with mesh and autologous fascia lata during RSC at a 
single institution by a single Female Pelvic Medicine and Reconstructive (FPMRS) 
fellowship trained surgeon. We report the operative and postoperative outcomes 
associated with mesh compared to autologous fascia lata. The hypothesis is that although 
the complications and operative times will likely differ, fascia lata will be non-inferior to 
mesh and will avoid mesh related complications.   
Materials and Methods 
This study was approved by the Institutional Review Board of Indiana University. A 
prospective non-randomized case comparison trial was designed and conducted at a single 
institution between November 2017 and December 2019. Eligible patients included 
women undergoing RSC with or without concomitant supracervical hysterectomy and/or 
urethral sling. All patients who underwent RSC during the study period were analyzed. The 
technique has been previously described.11, 13 
Patients were not randomized. The decision to use mesh versus autologous fascia lata was 
the result of an informed discussion and shared decision making between the physician 
and patient during preoperative counseling. The associated risks and benefits unique to 
each were described, including the FDA black box warnings (2008, 2011) regarding 
utilization of mesh as well as the risk of seroma, hematoma, thigh numbness, pain, muscle 
bulge, and DVT associated with fascia lata.14 The fascia was primarily harvested from the 
right lower extremity unless the patient had prior lower extremity surgery or specific 
laterality request. 
Patient data was extracted from medical records and patient surveys. Data analyzed 
included preoperative demographics, operative timing, postoperative hospital stay, 
surgical complications, Pelvic Organ Prolapse Quantification (POP-Q) exam, and patient 
reported outcomes including Urogenital Distress Inventory-6 (UDI-6) and Incontinence 
Impact Questionnaire-7 (IIQ-7).15  
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POP-Q stage was defined according to standard criteria as defined by the International 
Continence Society and American Urogynecologic Society.16 Recurrence was defined as > 0 
in any compartment on postoperative POP-Q exam (Aa, Ba, Ap, Bp). Recurrence at the 
apex was defined as ≥2cm of apical descent as determined by point C relative to total 
vaginal length. Complications were categorized using the Clavien-Dindo (CD) classification 
system.17  
Harvest of the Fascia Lata graft 
The surgical technique has been previously described.19 A key element is to begin 
harvesting at least 5 cm cephalad and lateral to the patella after identifying Gerdy’s 
Tubercle on the anterolateral aspect of the tibia, the point at which the tensor fascia lata 
coalesces into the iliotibial band. The longitudinal integrity of the ileotibial band must 
never be compromised making its identification crucial (Figure 1). Using malleable 
retractors and blunt dissection a sizeable graft can be harvested from a 4cm incision. The 
graft can then be fashioned in a Y-configuration or sling using non-absorbable 0-
monofilament (Figures 2,3).  
Statistical Analysis 
Statistical comparisons were principally performed preoperatively and at the most recent 
post-operative visit for each patient using paired t-test.  All statistical analyses were 
conducted with STATA SE version 16 (College Station, TX) as well as Microsoft Excel 
(Microsoft, Redmond, WA). Continuous variables were summarized using means and 
medians. Categorical variables were summarized using frequencies and percentages. 
Continuous variables were analyzed using 2 tailed t-test and categorical variables were 




A total of 64 women elected to undergo RSC from 2017 through 2019. Nineteen (29.7%) 
elected autologous fascia lata RSC and 45 (70.3%) chose mesh RSC. Baseline clinical 
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characteristics were similar between the surgical groups and are summarized in Table 1. 
Women who elected to undergo fascia lata graft harvest tended to be younger (mean age 
59.3±12.9 years vs. 67.9±10.7 years, p = 0.01). Gravidity was 2.3 vs. 3.3 (p=0.03), parity 
was 2.1 vs. 3.0 (p=0.02), and the majority were by vaginal delivery (1.8 vs. 2.9, p=0.01). 
Women receiving autologous grafts were more likely to be diabetic (p=0.01), but no 
difference was seen with regard to BMI or smoking status. Women receiving autologous 
grafts were also more likely to receive concomitant fascia slings (p<0.001), and those 
undergoing mesh SCP were more likely to undergo mesh sling instead of fascia sling, but 
there were no significant differences between the two groups regarding other 
concomitant procedures including supracervical or total hysterectomy, anterior or 
posterior colporrhaphy, or enterocele repair. Pooled analysis of either concomitant mid-
urethral or fascia sling in women receiving autologous grafts vs. mesh demonstrated no 
difference. 
Symptomatically, patients undergoing mesh vs. fascia lata had no difference in 
preoperative frequency, urgency, or incontinence (Table 1). There were no significant 
differences in patient-reported UDI-6 and IIQ-7 surveys. Preoperatively, pelvic 
measurements according to POP-Q exam were similar in all categories as well as POP-Q 
stage. At the time of surgery, all patients had ≥2cm apical descent with median POP-Q 
stage of 3 in both groups.  
Operative Details 
Operative details are outlined in Table 2. Eight of 19 (42.1%) underwent concomitant 
robotic supracervical hysterectomy in the fascia lata group compared to 16/45 (35.6%) in 
the mesh group (p=0.78). The average operative time for RSC with fascia was 288±39 
minutes compared to 237±31 minutes for mesh (p<0.001). Harvesting fascia required a 
mean of 24.8±7.4 minutes. There were 6 (31.6%) patients in the fascia group who 
underwent concomitant pubovaginal autologous sling and 8 (17.8%) patients in the mesh 
group who underwent concomitant mid-urethral mesh sling. Both mesh and fascia were 
secured to the vaginal wall using a running delayed absorbable 2-0 monofilament suture 
with three non-absorbable 0 monofilament sutures for sacral fixation (range 2-4) as 
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described previously.13 The average hospital stay for both groups was 1.0±0.7 days. There 
was no difference between the two groups regarding estimated blood loss and 
postoperative urinary retention requiring a foley catheter. There were no patients 
requiring catheterization at the one month-mark.  
For autologous fascia lata harvest, the average length of the graft was 18.3±2.5cm and 
width was 4.2±1.4 cm (see Figure 1).  
Postoperative Outcomes 
Intra-group outcomes demonstrated postoperative improvement on all clinical and patient 
reported outcomes for fascia lata (Table 3) and mesh (Table 4).  An inter-group 
comparison of clinical and patient reported outcomes is displayed in Table 5. Overall 
patient reported outcomes were similar between fascia lata and mesh. There was 
increased urinary frequency in the mesh group (p=0.03) and increased de novo stress 
incontinence seen in the fascia lata group (p=0.02). With regard to patient-reported 
outcomes, there was no difference seen on the UDI-6, but an increased total score in the 
fascia lata group on the IIQ-7 (p=0.05). Anatomic outcomes were not significantly different 
between groups. The vast majority of patients in both groups exhibited POP-Q stage 2 or 
less (94.8% in fascia and 97.8% in mesh). One patient in the fascia lata group exhibited 
failure in both the anterior and apical compartments. The mesh group had five recurrences 
in the posterior compartment and one failure in the anterior compartment at a combined 
mean follow-up of 12.1±8.2 months. The differences in recurrence were not statistically 
significant (Table 5).  
Postoperative Complications 
In the fascia lata group, one patient developed acute tubular necrosis which resolved with 
intravenous fluid resuscitation (CD-II), one developed unilateral hydronephrosis requiring 
ureteral stent and balloon dilation of the affected ureter which is resolved on follow up 
ultrasound 3 months later (CD-IIIb), one hematoma at the harvest site requiring 
transfusion (CD-II), and one ipsilateral DVT (CD-II). In the mesh group, one mesh erosion 
was noted requiring vaginal mesh excision (CD-IIIb). 
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Morbidity from the harvest site is summarized in Table 6. Notably, this included swelling 
(10.5%), paresthesia that resolved (5.3%), paresthesia that remained unresolved (5.3%), 
hematoma (5.3%), and seroma (10.5%). Notably, there were no complaints of persistent 
pain and no wound infections.  
Discussion 
There is limited literature on autologous fascia lata sacral colpopexy, mostly consisting of 
small case series with short-term outcomes.12, 18 This is the first comparison to our 
knowledge between RSC with autologous fascia lata vs. mesh.  Despite some noted 
limitations, this study demonstrates that RSC with autologous fascia lata has similar short-
term anatomic outcomes to mesh for women with apical POP.  
What remains unknown is the long-term durability of autologous fascia lata. Freeze-dried 
cadaveric fascia lata has previously demonstrated poor 12-month outcomes and poor 5 
year outcomes with 62% success rate compared to 93% for mesh, however, that analysis 
was post-hoc and included only 58/100 original subjects.19,20 The hypothesis is that 
cadaveric fascia promotes an immune response that compromises the integrity of the 
tissue. It is possible that autologous fascia lata may prove more durable given that it does 
not promote the immune response.  
This investigation aimed to capture both anatomic and patient reported outcomes. There 
was a single anatomic failure within the fascia group with apical prolapse and anterior wall 
laxity, which will require surgical revision. There were no posterior recurrences in the 
fascia group, while the mesh group had five posterior failures and a single recurrent 
cystocele. The recurrent cystocele required revision with an anterior vaginal wall 
suspension. It is important to note that none of the patients received a concomitant 
anterior nor posterior repair at the time of SCP, a practice that some follow and that might 
decrease the compartment specific failure rate.   It is also important to note that in a small 
series like this the concomitant PV sling might support the anterior vaginal wall more 
effectively than the mesh sling, and both might support better than no concomitant 
procedure, although slings are not intended to do this.    The primary outcome was apical 
failure, which would not be influenced by concomitant procedures such as sling , anterior 
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repair, posterior repair, or enterocele.  The compartment specific outcomes, as well as the 
patient reported outcomes, will be influenced by an unbalanced application of these 
procedures.  For this reason Fisher’s exact test was performed to detect bias that might 
suggest one cohort received compartment specific repairs more often than the other.  
Those results appear in Table 2.  
Our findings are similar to Scott et al. who demonstrated no recurrent apical prolapse, but 
a 25% recurrence of anterior vaginal wall prolapse in twelve patients who underwent RSC 
with autologous fascia lata.12 Alternatively, Latini et al reported a 100% success rate 
without apical descent at 18 months in a group of 10 women who underwent open sacral 
colpopexy with autologous fascia lata.5 This suggests that RSC with autologous fascia 
provides comparable tensile strength in the short term for apical fixation to synthetic 
alternatives.  The success rates can be expected to decline with longer follow up, and our 
intention is to follow the fascia cohort for 5 years and compare directly with the mesh 
cohort. Furthermore, the data describes will be used for power calculations in the design 
of a prospective RCT to further explore the hypothesis.  
The low rates of serious adverse events associated with both methods is consistent with 
prior clinical studies.5 Our mesh exposure rate of 2.2% is comparable to the 1.5-8% noted 
in a recent review of 13 randomized clinical trials describing sacral colpopexy.4 The single 
patient who suffered a mesh exposure event requested a revision, which was successful. 
The immediate morbidity of the fascia lata harvest site must be taken into careful 
consideration and discussed during preoperative counseling. Patients undergoing graft 
harvest are at risk for site-specific complications including site swelling, numbness, 
hematoma, and seroma, which has been previously described.12 The majority of these 
were self-limiting and typically resolved with expectant management. No patients 
demonstrated functional or ambulatory deficits as a result of graft harvest. There was a 
single incidence of harvest site hematoma requiring transfusion and one DVT requiring 
anticoagulation. The DVT is troublesome and all fascia lata harvest patients are now given 
prolonged venous thromboembolism prophylaxis similar to that in lower extremity 
orthopedic procedures.21 Another patient required aspiration of a thigh seroma. However, 
postoperative seromas are usually small and resolve on their own and as such our group 
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discourages intervention. These findings highlight the importance of preoperative 
counseling and raise the important question of how much harvest site morbidity is 
acceptable to avoid the risks of synthetic mesh.  
Quality of life is integral to guiding treatment and evaluating the treatment outcomes of 
POP. This work captured patient reported outcomes using the validated IIQ-7 and UDI-6 
questionnaires which reflect urinary symptoms, pelvic discomfort, and quality of life 
measures related to POP. Both groups demonstrated significant improvement in patient-
reported outcomes postoperatively. The fascia lata group reported higher IIQ-7 scores 
compared to the mesh group, which parallels an increase in de novo SUI found in this 
group. However, none of the patients reporting new onset SUI have elected to proceed 
with sling placement suggesting symptoms were mild.  
Interestingly, women that elected to undergo fascial harvest tended to be younger. The 
reasoning behind this could be two-fold. The younger population may be more concerned 
regarding the long-term risks of mesh including vaginal erosion and dyspareunia. They also 
may be more willing to try a new technique and expect a quick recovery despite the extra 
harvest site incision.  
Weaknesses and Limitations 
This work has several weaknesses that should be mentioned. It is a single surgeon, single 
institution case series which limits the generalizability of the findings. The numbers were 
small and the follow up was relatively short at 12.1 months. The groups were not evenly 
matched, the fascia lata group was significantly younger and less parous than the mesh 
group.  This can of course introduce bias. Despite a significant difference in age and parity 
between the two groups, the preoperative POP-Q measurements, UDI-6, and IIQ-7 
responses were similar. 
Conclusions 
This is the first prospective comparison of RSC using autologous fascia lata to mesh. Fascia 
lata RSC appears to have comparable short-term success rates to mesh RSC and 
acceptable, but higher than expected morbidity related to the graft site with increased 
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operative time. The knowledge gained and questions raised underscore the need for a 
randomized controlled trial. An instructive video describing the technique has been 
published and the technique is possible for any surgeon familiar with RSC to learn.22 
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Table 1: Demographics, Baseline Pelvic Measurements, and Urinary Symptoms 
Variable Fascia (N=19) Mesh (N=45) P-value
Age at Sacral Colpopexya 59 (41-91) 68 (35-78) 0.01 
Race 
 White 16 (84.2%) 41 (91.1%) NS 
    Black 3 (15.8%) 4 (8.9%) 
BMIa 26 (18-34) 29 (20-45) NS 
Diabetes 5 (26.3%) 1 (2.2%) 0.01 
Current Smoker 0 3 (6.7%) NS 
Graviditya 2.3 (0-6) 3.3 (1-8) 0.03 
Paritya 2.1 (0-4) 3.0 (1-7) 0.02 
Cesarean Deliveriesa 0.2 (0-4) 0.1 (0-4) NS 
Vaginal Deliveriesa 1.8 (0-4) 2.9 (1-7) 0.01 
Prior Hysterectomy 7 (36.8%) 22 (48.9%) NS 
Prior SUI/POP Surgery 3 (15.8%) 13 (28.9%) NS 
Voids/24hours b 7.9 ± 4.3 15.9 ± 19.3 NS 
Pads/24hours b 1.2 ± 1.3 1.3 ± 1.8 NS 
Urge Incontinence 9 (47.4%) 16 (35.6%) NS 
Stress Incontinence 7 (36.8%) 9 (20.0%) NS 
Postvoid Residual (mL) b 51.1 ± 66.9 62.6 ± 81.9 NS 
UDI-6 b 11 ± 4.4 10 ± 4.5 NS 
IIQ-7 b 11 ± 8.4 11 ± 7.4 NS 
POPQ Valuec 
Aa 1 (0 to 3) 0 (-3 to 3) NS 
Ba 1.5 (0 to 6) 2 (-2 to 8) NS 
Ap -1.5 (-3 to 0) -2 (-3 to 3) NS 
Bp -1 (-3 to 1) -1 (-3 to 3) NS 
C -5 (-8 to -2) -5 (-8 to 5) NS 
GH 3 (2 to 5) 3 (3 to 5) NS 
PB 3 (2 to 3) 3 (1 to 5) NS 
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TVL 8 (6 to 10) 8 (6 to 11) NS 
POPQ Stagec 3 (2 to 4) 3 (2 to 4) NS 
Stage 0 0 0 
Stage 1 0 0 
Stage 2 9 (47.4%) 17 (37.8%) 
Stage 3 10 (52.6%) 24 (53.3%) 
Stage 4 0 4 (8.9%) 
BMI, body mass index; SUI/POP, stress urinary incontinence/pelvic organ prolapse; UDI-6, 
Urogenital Distress Inventory-6; IIQ-7, Incontinence Impact Questionnaire-7; NS, not 
significant; asummarized by mean (range); bsummarized by mean (standard deviation); 
csummarized by median (range) 
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Table 2: Operative Details 
Variable Fascia (N=19) Mesh (N=45) P-value
Operative Time (min)a 288 (210-365) 237 (161-326) <0.001 
Fascia Harvest Time (min)a 25 (18-40) NA 
Estimated Blood Loss (mL) a 33 (20-52) 28 (10-80) 0.11 
Length of Stay (Days)b 1 (0-4) 1 (0-3) 0.38 
Concomitant Supracervical 
Hysterectomy 8 (42%) 16 (36%) 0.78 
Concomitant total hysterectomy 1 (5%) 3  (7%) 1 
Concomitant mid urethral sling 0 (0%) 8 (18%) 0.09 
Concomitant fascia sling 6 (32%) 0 (0%) <0.001 
Concomitant anterior repair 0 (0%) 0 (0%) 
Concomitant posterior repair 0 (0%) 0 (0%) 
Concomitant enterocele repair 18 (95%) 40 (89%) 0.66 
Required Catheterization POD1 5 (26%) 4 (9%) 0.11 
POD1, postoperative day one; a summarized by mean (range); bsummarized by median 
(range) 
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Table 3: Combined Outcomes for Fascia Lata 
UDI-6, Urogenital Distress Inventory-6; IIQ-7, Incontinence Impact Questionnaire-7; 
asummarized by mean(standard deviation); bsummarized by median (range) 
Variable Preoperative Postoperative P-
value 
UDI-6a 10 ± 4.5 4.3 ± 3.8 0.004 
IIQ-7a 11 ± 7.4 2.2 ± 5.1 0.02 
POPQ Valueb 
Aa 1 (0 to 3) -3 (-3 to 2) <0.001 
Ba 1.5 (0 to 6) -3 (-3 to -3) <0.001 
Ap -1.5 (-3 to 0) -3 (-3 to -1) <0.001 
Bp -1 (-3 to 1) -2 (-3 to 0) 0.01 
C -5 (-8 to -2) -8 (-10 to -6) <0.001 
GH 3 (2 to 5) 3 (3 to 4) 0.33 
PB 3 (2 to 3) 3 (3 to 3) 0.16 
TVL 8 (6 to 10) 9 (7 to 10) 0.13 
POPQ Stageb 3 (2 to 4) 1 (0 to 3) 0.0001 
Stage 0 0 4 (21.1%)
Stage 1 0 6 (31.6%)
Stage 2 9 (47.4%) 8 (42.1%)
Stage 3 10 (52.6%) 1 (5.2%) 
Stage 4 0 0 
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Table 4: Combined Outcomes for Mesh 
Variable Preoperative Postoperative P-value
UDI-6a 11 ± 4.4 5.5 ± 3.0 <0.001 
IIQ-7a 11 ± 8.4 4.9 ± 4.6 <0.001 
POPQ Valueb 
Aa 0 (-3 to 3) -3 (-3 to 0) <0.001 
Ba 2 (-2 to 8) -2 (-3 to 0) <0.001 
Ap -2 (-3 to 3) -2 (-3 to 2) 0.002 
Bp -1 (-3 to 3) -2 (-3 to 2) 0.007 
C -5 (-8 to 5) -8 (-10 to -5) <0.001 
GH 3 (3 to 5) 3 (2 to 5) 0.01 
PB 3 (1 to 5) 3 (2 to 5) NS 
TVL 8 (6 to 11) 8 (5 to 10) NS 
POPQ Stageb 3 (2 to 4) 2 (0 to 3) <0.001 
Stage 0 0 5 (11.1%)
Stage 1 0 7 (15.6%)
Stage 2 17 (37.8%) 32 (71.1%)
Stage 3 24 (53.3%) 1 (2.2%) 
Stage 4 4 (8.9%) 0 
UDI-6, Urogenital Distress Inventory-6; IIQ-7, Incontinence Impact Questionnaire-7; NS, 
not significant; asummarized by mean (standard deviation); bsummarized by median 
(range) 
Page 22 of 28 
22 
Table 5: Postoperative Comparison Fascia Lata vs. Mesh 
Variable Fascia (N=19) Mesh (N=45) P-value
Voids/24hoursa 4.4 ± 2.0 6.6 ± 3.6 0.03 
Pads/24hoursa 1.2 ± 1.3 0.66 ± 1.7 0.20 
Urge Incontinence 5 (26.3%) 8 (17.8%) 0.74 
Stress Incontinence 4 (21.1%) 1 (2.2%) 0.02 
Postvoid Residual (mL) a 30 ± 74.2 31 ± 41.5 0.96 
UDI-6a 5.5 ± 3.0 4.3 ± 3.8 0.25 
IIQ-7a 4.9 ± 4.6 2.2 ± 5.1 0.05 
POPQ Valueb 
Aa -3 (-3 to 2) -3 (-3 to 0) 0.49 
Ba -3 (-3 to -3) -2 (-3 to 0) 0.41 
Ap -3 (-3 to -1) -2 (-3 to 2) 0.04 
Bp -2 (-3 to 0) -2 (-3 to 2) 0.13 
C -8 (-10 to -6) -8 (-10 to -5) 0.22 
GH 3 (3 to 4) 3 (2 to 5) 0.62 
PB 3 (3 to 3) 3 (2 to 5) 0.65 
TVL 9 (7 to 10) 8 (5 to 10) 0.14 
POPQ Stageb 1 (0 to 3) 2 (0 to 3) 0.12 
Stage 0 4 (21.1%) 5 (11.1%)
Stage 1 6 (31.6%) 7 (15.6%)
Stage 2 8 (42.1%) 32 (71.1%)
Stage 3 1 (5.2%) 1 (2.2%) 
Stage 4 0 0 
Recurrent Cystocele 1 (5.3%) 1 (2.2%)  0.45 
Recurrent Rectocele 0 5 (11.1%) 0.31 
Recurrent Apical Descent 1 (5.3%) 0 0.30 
Follow-Up (Months) a 12.1 ± 8.7 
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UDI-6, Urogenital Distress Inventory-6; IIQ-7, Incontinence Impact Questionnaire-7; 
asummarized by mean (standard deviation); bsummarized by median (range) 
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Table 6: Site-Specific Complications Associated with Fascia Lata Harvest 
Complication Number of Patients (N=19) 
Swelling 2 (10.5%) 
DVT 1 (5.3%) 
Pain 0 
Infection 0 
Paresthesia (Resolved) 1 (5.3%) 
Paresthesia (Unresolved) 1 (5.3%) 
Hematoma 1 (5.3%) 
Seroma 2 (10.5%) 
DVT, deep vein thrombosis 
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Figure 1: Sample harvest site and fascia lata graft. This figure demonstrates a 16cm fascia 
lata graft obtained through a 4 cm skin incision. The graft is harvested anterior to the 
iliotibial band. 
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Figure 2: Sample fascia harvest. Multiple fascial pieces can be obtained from a single 
incision and harvest of fascia lata. This demonstrates fascia configured for posterior (P), 
anterior (AN), sacral (S), and pubovaginal sling (TVT).  
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Figure 3: Y configuration. The fascia graft is configured into a Y configuration using 0-non-
absorbable monofilament. Two leaflets will be secured to the anterior and posterior 
vagina, while the segment labeled “S” will be secured to the sacrum. 
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Abbreviations Used 
RSC = robotic sacral colpopexy 
POP-Q = Pelvic Organ Prolapse Quantification 
CD = Clavien-Dindo 
POP = pelvic organ prolapse 
FDA = Food and Drug Administration 
FPMRS = Female Pelvic Medicine and Reconstructive Surgeon 
UDI-6 = Urogenital Distress Inventory-6 
IIQ-7 = Incontinence Impact Questionnaire-7 
